Publishing Service

Polishing & Checking

Journal of Zhejiang University SCIENCE B

ISSN 1673-1581(Print), 1862-1783(Online), Monthly

Infliximab treatment in two Chinese patients with psoriatic arthritis

Abstract: Psoriatic arthritis (PsA) is a rheumatoid factor (RF)-seronegative systemic inflammatory disorder associated with psoriasis. Current treatment for PsA in China is still focused on disease modifying anti-rheumatic drugs (DMARDs). In this paper, we report two Chinese patients with active longstanding PsA treated with infliximab, a human-mouse chimeric monoclonal antibody against tumor necrosis factor alpha (TNF-α). The results show that infliximab acted quickly and effectively in relieving peripheral and axial symptoms and refractory skin lesions, even in recombinant human TNF-α receptor (rhTNFR)-resistant case. The take-home message from our cases is that infliximab is a useful therapeutic option for refractory PsA, especially when a patient has a combination of psoriasis and psoriatic arthritis. Further local evidence and experience must be accumulated in order to make anti-TNF-α therapy more accessible to PsA patients in China.

Key words: Refractory psoriatic arthritis, Skin lesions, Infliximab, Anti-tumor necrosis factor alpha (TNF-α) treatment


Share this article to: More

Go to Contents

References:

<Show All>

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





DOI:

10.1631/jzus.B1000087

CLC number:

R593.2

Download Full Text:

Click Here

Downloaded:

560

Clicked:

1135

Cited:

0

On-line Access:

2010-10-05

Received:

2010-03-11

Revision Accepted:

2010-07-05

Crosschecked:

2010-09-13

Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952276; Fax: +86-571-87952331; E-mail: jzus@zju.edu.cn
Copyright © 2000~ Journal of Zhejiang University-SCIENCE